CVS Agrees to Pay $38M to Settle Insulin Fraud Claims

CVS agrees to pay $38M to settle insulin fraud claims

For a decade, CVS knew it was skirting rules meant to limit overprescribing but did nothing to stop, according to the Department of Justice.

CVS will pay almost $38M in insulin pen settlement

The retailer admits to receiving payments for pen refills that were ineligible for reimbursement

CVS $37.8M Settlement Ends Decade of Alleged Insulin Pen Overbilling

In a settlement that echoes like a warning shot across the pharmacy industry, CVS Pharmacy Inc. agreed Tuesday to pay $37.76 million to resolve federal allegations that it spent a decade overdispensing and overbilling government healthcare programs for insulin pens. Prosecutors say the violations, stretching from 2010 to 2020, inflated claims and broke trust in CVS $37.8M settlement resolves decade-long insulin pen overbilling allegations under F